Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development
Search Refinements
Search Results: Drug Discovery & Development
1-15 of 4998 results
Cardiff University scientists find potential root cause for asthma
By PBR Staff Writer
Scientists from the Cardiff University have discovered the potential root cause and a novel treatment for asthma, a chronic lung disease affecting 300 million people worldwide.
Drug Research > Drug Discovery & Development > News
ThromboGenics begins evaluation of Jetrea to treat retinal vein occlusion
By PBR Staff Writer
Belgium-based biopharmaceutical firm ThromboGenics has started evaluating Jetrea (ocriplasmin) as a potential treatment for retinal vein occlusion (RVO).
Drug Research > Drug Discovery & Development > News
Technology Platform
Including: Effervescent tables, effervescent granular in sachet, granular in sachets, orally disintegrating tablets, extended release tablets and soft gelatin capsules.
Drug Research > Drug Discovery & Development > Products
A High Quality Formulation Development and Manufacturing Company
| By Alpex Pharma
Our predominant focus is the development of solid dosage forms to deliver drugs directly into the oral cavity in order to potentially improve both the bioavailablity of the drug as well as patient compliance and convenience to it. Alpex Pharma has 28 years of cGMP manufacturing experience and formulation development.
Drug Research > Drug Discovery & Development > White Papers
Lilly reports positive results from Phase III trial of ixekizumab to treat psoriatic arthritis
By PBR Staff Writer
Eli Lilly and Company has announced that a Phase III trial (SPIRIT-P1) of its investigational medicine, ixekizumab, met the primary endpoint in the treatment of patients with psoriatic arthritis (PsA), a progressive, chronic and destructive disease.
Drug Research > Drug Discovery & Development > News
TetraLogic, Merck enter oncology clinical trial collaboration
By PBR Staff Writer
US-based biopharmaceutical firm TetraLogic Pharmaceuticals has entered into an oncology clinical study collaboration with Merck.
Drug Research > Drug Discovery & Development > News
Oncolytics' Reolysin gets orphan drug designation for malignant gliomas treatment
By PBR Staff Writer
Canadian biotechnology firm Oncolytics Biotech has secured orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for its lead product candidate, Reolysin, to treat malignant glioma.
Drug Research > Drug Discovery & Development > News
Sun Pharma, Technion to develop new class of oncology drugs
By PBR Staff Writer
India-based Sun Pharmaceutical Industries and Israel's Technion University have entered into an exclusive worldwide research and license agreement for the development of new class of oncology drugs.
Drug Research > Drug Discovery & Development > News
Vetter announces Oliver Albrecht has been appointed Managing Director
Vetter, a leading contract development and manufacturing organization that specializes in aseptic manufacturing, today announced that the company’s Advisory Board unanimously appointed Oliver Albrecht as a new Managing Director effective April 1, 2015. Albrecht replaces Max Horn as a Vetter Managing Director who left the company in June 2014.
Drug Research > Drug Discovery & Development > Press Releases
Reata gets FDA orphan drug status for bardoxolone methyl to treat PAH
By PBR Staff Writer
Reata Pharmaceuticals, a US-based developer of breakthrough medicines, has secured orphan drug designation from the FDA Office of Orphan Products Development (OOPD) for bardoxolone methyl to treat pulmonary arterial hypertension (PAH).
Drug Research > Drug Discovery & Development > News
US FDA modifies partial clinical hold on Tekmira's TKM-Ebola IND application
By PBR Staff Writer
The US Food and Drug Administration (FDA) has notified Tekmira Pharmaceuticals that the partial clinical hold on its investigational new drug (IND) application for TKM-Ebola, an anti-Ebola virus RNAi therapeutic, has been modified to permit repeat dosing of healthy volunteers at a dose of 0.24 mg/kg/day.
Drug Research > Drug Discovery & Development > News

PBR Supplier Recommendations

Therapure Biopharma - Contract Protein Development and Manufacturing
Therapure Biopharma is a Contract Development and Manufacturing Organization (CDMO) that specializes in the development, scale up and manufacture of complex biologics. Therapure operates a modern 130,000 ft2 cGMP facility in the Greater Toronto Area that is equipped with Class A to C clean rooms, QC and analytical labs, clinical and commercial scale manufacturing suites, mammalian cell culture production capability with upstream and downstream processing and aseptic fill/finish capacity. ... Drug Research > Drug Discovery & Development > Suppliers
Vetter Pharma International - High-Quality Aseptically Pre-Filled Injection Systems
From preclinical development through commercial supply.... Drug Research > Drug Discovery & Development > Suppliers
ERT - Getting it done. Right.
ERT is a leading global provider of high-quality patient safety and efficacy endpoint data collection solutions for use by biopharmaceutical companies during clinical drug development. ERT delivers a combination of technology, services, and consulting that increase the accuracy and reliability of patient data and improve the efficiency of the clinical development process throughout the product lifecycle.... Drug Research > Drug Discovery & Development > Suppliers
Eppendorf - We Know Bioprocessing
Eppendorf is a leading life science company that develops and sells instruments, consumables, and services for liquid-, sample-, and cell handling in laboratories worldwide. Its product range includes pipettes and automated pipetting systems, dispensers, centrifuges, mixers, spectrometers, and DNA amplification equipment as well as ultra-low temperature freezers, fermentors, bioreactors, CO² incubators, shakers, and cell manipulation systems. Consumables such as pipette tips, test tubes, microtiter plates, and disposable bioreactors complement the range of highest-quality premium products.... Drug Research > Drug Discovery & Development > Suppliers
Biovian - cGMP Contract Manufacturing of Biopharmaceuticals
Biovian is a dynamic and effective new generation one-stop-shop CMO in cGMP contract manufacturing of biopharmaceuticals. Biovian's services cover the full range from antigen isolation, expression, vector construction, cell line cultivation, cGMP protein purification to product fill and finish.... Drug Research > Drug Discovery & Development > Suppliers
See more

PBR White Paper Recommendations

A High Quality Formulation Development and Manufacturing Company By Alpex Pharma
Our predominant focus is the development of solid dosage forms to deliver drugs directly into the oral cavity in order to potentially improve both the bioavailablity of the drug as well as patient compliance and convenience to it. Alpex Pharma has 28 years of cGMP manufacturing experience and formulation development.... Drug Research > Drug Discovery & Development > White Papers High Cell Density Fermentation of Escherichia coli Using the New Brunswick™ BioFlo® 115 By Eppendorf
This application note presents a successful example of a high density fermentation of Escherichia coli (E. coli) using the New Brunswick BioFlo 115 benchtop, autoclavable fermentor from Eppendorf. The highest optical density (OD600) achieved in this study was 140 at 11 hours (h) without optimized fermentation medium and conditions.... Drug Research > Drug Discovery & Development > White Papers Best Practices for Streamlining Electronic Implementation of Established COAs; Copyright January 2015 By ERT
This paper addresses the best practices for building an electronic Clinical Outcome Assessment (eCOA) solution in support of clinical research as it relates to the operational and licensing compliance aspects of administering COAs on electronic platforms.... Drug Research > Drug Discovery & Development > White Papers Symptoms and Impact of COPD Assessed by an Electronic Diary in Patients with Moderate-to-Severe COPD: Psychometric Results from the SHINE Study; International Journal of COPD; January 2015. By ERT
This paper presents the results of psychometric assessment data from a COPD eDiary developed by Novartis to provide a more detailed assessment of symptom frequency and severity and their impact on patients with COPD.... Drug Research > Drug Discovery & Development > White Papers The Use of Ambulatory Blood Pressure Monitoring in Drug Development; Copyright, January 2015 By ERT
This white paper delves into the basics of blood pressure, along with the well-documented limitations of standard and digital office blood pressure measurements. It reviews ABPM device functionality, common drug classes where blood pressure monitoring comes into play and compares the advantages and disadvantages of different monitoring options in clinical studies.... Drug Research > Drug Discovery & Development > White Papers See more
1-15 of 4998 results